Carvykti denied as non-formulary by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Carvykti as Non-Formulary

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy that may not appear on Aetna's standard formulary tier structure or may appear only on a specialty tier requiring additional authorization steps. A non-formulary denial means the drug was not listed on your specific plan's covered drug list, or that it requires a formulary exception before coverage will be extended. For CAR-T therapies, this situation is common because the products are high-cost specialty biologics that plans often manage through a separate oncology pathway rather than the standard pharmacy benefit formulary.

## Why This Denial Is Appealable

When a drug has FDA approval and is the standard of care for a condition, most plans are required to process a formulary exception request — and to grant it when no formulary alternative is clinically appropriate. CAR-T therapies have no generic or biosimilar equivalents, and no formulary alternative exists that is clinically interchangeable for the approved indication. This makes Carvykti a strong candidate for a formulary exception. Additionally, many state insurance regulations and some federal guidance require that specialty tier exceptions be granted when the requested drug is medically necessary and no equivalent formulary option exists.

## Federal Appeal Framework

• Formulary exception request: File a formulary exception request simultaneously with your internal appeal. Most plans have a separate exception pathway with its own timeline.
• Internal appeal: Under ERISA §503 or state law, you have the right to a full-and-fair internal review within the deadline in your denial letter.
• External review: Under ACA §2719, after exhausting internal processes you may seek independent external review within approximately four months of the final denial.
• Expedited review: Given the serious nature of the underlying condition, request expedited processing at every step.

## Documentation to Gather

• No-formulary-alternative statement: Your oncologist should document in writing that no formulary-listed drug exists that is clinically interchangeable with Carvykti for your specific indication and line of therapy.
• FDA approval and indication confirmation: Print the Carvykti prescribing information from Drugs@FDA. Your oncologist should confirm your case falls within the approved indication.
• Prior-therapy history: Complete documentation of all prior lines of therapy, establishing that the patient meets the criteria for the Carvykti indication.
• Medical-necessity letter: A letter from the treating hematologist-oncologist stating that Carvykti is medically necessary, that no covered formulary alternative will serve the same therapeutic purpose, and that denial of coverage will result in a gap in medically necessary care.
• Plan documents: Obtain your plan's formulary exception policy and identify the specific grounds on which exceptions are granted.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria from your plan documents or the denial letter. Build a response table: left column lists each exception criterion; right column cites the specific document satisfying it. For a non-formulary appeal of a CAR-T therapy, the absence of a clinically equivalent formulary alternative is almost always the dispositive argument — make it the first and most prominently documented point in your submission.